Authors
Latest:
Dr. Kaufman on T-VEC in MelanomaHoward L. Kaufman, MD, chief surgical officer, associate director for Clinical Science, surgical oncologist, Rutgers Cancer Institute of New Jersey, discusses oncolytic immunotherapy talimogene laherparepvec (T-VEC; Imlygic) for treatment of patients with melanoma, as well as the agent's side effect profile.
Latest:
The Search for Immune-Specific Biomarkers Is in Full SwingAn improved understanding of how the immune system recognizes and eradicates cancer cells, along with advances in drugs that effectively promote antitumor immune responses, is revolutionizing the field of cancer therapy.
Latest:
Dr. Sandler Discusses Hypofractionation in Prostate CancerHoward M. Sandler, MD, chair, Department of Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, director, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses hypofractionation in prostate cancer.
Latest:
Dr. Howard S. Hochster on TAS-102 Compared to 5FUHoward S. Hochster, MD, professor of Medicine and Associate Director for Clinical Sciences, Yale Cancer Center, discusses the potential of TAS-102 for colorectal cancer.
Latest:
Dr Hochster on the Importance of Clinical Trial Participation in Cancer CareHoward S. Hochster, MD, discusses the importance of clinical trial participation for patients with cancer and highlights the use of precision medicine across the treatment armamentarium.
Latest:
Dr. Sandler on Docetaxel With Hormonal and Radiation Therapy in Prostate CancerHoward Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, discusses results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.
Latest:
Dr. Burris on the Exploration of PARP Inhibitors in TNBCHoward A. “Skip” Burris, III, MD, FASCO, FACP, discusses the exploration of PARP inhibitors in triple-negative breast cancer.
Latest:
Dr. Burris on Molecular Profiling in Breast CancerHoward "Skip" A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses the impact of molecular profiling in breast cancer.
Latest:
EHRs in the Urology OfficeThe implementation of electronic health records to replace paper charts in urology practices is a recent phenomenon that is picking up some serious momentum.
Latest:
Unraveling the Layers: IDNs, ACOs, and the Future of Healthcare IntegrationThis recorded webinar features thought leader perspectives and key insights from HRA's newest research program - Understanding Integrated Delivery Networks.
Latest:
Treatment Patterns of Metastatic Triple-Negative Breast Cancer in US Community Practice SettingsFirst-line treatment patterns for metastatic triple-negative breast cancer are diverse, reflecting a lack of consensus and an unmet need for standardized therapy.
Latest:
Dr. Ford on Docetaxel in Esophagogastric CancerHugo Ford, MD, from the Addenbrooke's Hospital in Cambridge, UK, describes which patients with metastatic esophagogastric cancer derive the greatest benefit from second-line treatment with docetaxel.
Latest:
SABCS Interview SeriesThe January issue of OBTN featured highlights from the 32nd Annual San Antonio Breast Cancer Symposium (SABCS). We wrap up our SABCS coverage this month with interviews on denosumab with Alison Stopeck, MD, associate professor of medicine at the University of Arizona and director of the Clinical Breast Cancer Program at the Arizona Cancer Center; oral bisphosphonates with Rowan T.Chlebowski, MD, PhD, professor and chief of the Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles Medical Center; and adjuvant chemotherapy�induced alopecia with Hugues Bourgeois, MD, Centre Jean Bernard in Lemans, France.
Latest:
Advanced 3D MRI Technology Marks a Leap Forward in Glioblastoma ImagingAlthough advances have been made in imaging techniques for patients with glioblastoma multiforme, new tools are needed to supplement standard imaging sequences.
Latest:
Dr. Chen on Rapid Research Autopsy in Rare CancerHui-Zi Chen, MD, PhD, discusses the use of rapid research autopsy in metastatic ultra-hypermutated interdigitating dendritic cell sarcoma, an extremely rare cancer of dendritic origin that lacks a standardized treatment approach.
Latest:
Dr. Rana on the Rationale for Video Genetic Counseling in Prostate CancerHuma Q. Rana, MD, MPH, discusses the rationale for the ProGen trial, which compared the effectiveness of video education versus in-person genetic counseling for men with prostate cancer.
Latest:
Dr. Choi on Using Low-Dose CT Scans to Screen for Lung CancerHumberto Choi, MD, discusses using low-dose CT scans to screen patients with a high-risk of developing lung cancer.
Latest:
Dr. Lee on Potential Challenges With VLS-101 in MCL and DLBCLHun Ju Lee, MD, discusses potential challenges with VLS-101 in mantle cell lymphoma and diffuse large B-cell lymphoma.
Latest:
Dr. Khong on the Importance of BRCA Testing in Breast CancerHung Khong, MD, underscores the importance of testing for BRCA mutations in patients with breast cancer.
Latest:
Nivolumab Plus Relatlimab vs Nivolumab in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-047): Overall Survival and Melanoma-Specific Survival Outcomes at 3 YearsA 3 year survival update on the RELATIVITY-047 trial (NCT03470922), a global, randomized, double-blind phase 2/3 study comparing nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable stage III or IV melanoma.
Latest:
Dr. Aoun on Imaging Modalities in Prostate CancerHussein Aoun, MD, a radiologist at Barbara Ann Karmanos Cancer Institute, discusses the imaging modalities that are currently being used in prostate cancer and how they compare with conventional imaging modalities.
